Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The application of precision medicine in oncology requires in-depth characterisation of a patient's tumours and the dynamics of their responses to treatment. PATIENTS AND METHODS: We used next-generation sequencing of circulating cell-free DNA (cfDNA) to monitor the response of a KIT p.L576P-mutant metastatic vaginal mucosal melanoma to sequential targeted, immuno- and chemotherapy. RESULTS: Despite a KIT mutation, the response to imatinib was mixed. Unfortunately, tumours were not accessible for molecular analysis. To study the mechanism underlying the mixed clinical response, we carried out whole-exome sequencing and targeted longitudinal analysis of cfDNA. This revealed two tumour subclones; one with a KIT mutation that responded to imatinib and a second KIT-wild-type subclone that did not respond to imatinib. Notably, the subclones also responded differently to immunotherapy. However, both subclones responded to carboplatin/paclitaxel, and although the KIT-wild-type subclone progressed after chemotherapy, it responded to subsequent re-administration of paclitaxel. CONCLUSION: We show that cfDNA can reveal tumour evolution and subclonal responses to therapy even when biopsies are not available.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Distinct Sets of Genetic Alterations in Melanoma
Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.-B., LeBoit, P. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050092 · Cited by 2,747
Cited by
Liquid biopsies come of age: Towards implementation of circulating tumour DNA
Wan, J. C. M., Massie, C., Garcia-Corbacho, J., Mouliere, F., Brenton, J. D., Caldas, C., Pacey, S., Baird, R., & Rosenfeld, N. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.7 · Cited by 2,809
Integrating liquid biopsies into the management of cancer
Siravegna, G., Marsoni, S., Siena, S., & Bardelli, A. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.14 · Cited by 1,908
Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond
Keller, L., Belloum, Y., Wikman, H., & Pantel, K. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01047-5 · Cited by 401
Zill, O. A., Banks, K. C., Fairclough, S. R., Mortimer, S. A., Vowles, J. V., Mokhtari, R., Gandara, D. R., Mack, P. C., Odegaard, J. I., Nagy, R. J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3837 · Cited by 391
van der Pol, Y., & Mouliere, F. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.09.003 · Cited by 324
Metadata
- Authors
- Gremel, G., Lee, R. J., Girotti, M. R., Mandal, A. K., Valpione, S., Garner, G., Ayub, M., Wood, S., Rothwell, D. G., Fusi, A., Wallace, A., Brady, G., Dive, C., Dhomen, N., Lorigan, P., & Marais, R.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2016-10
- Volume
- 27
- Issue
- 10
- Pages
- 1959-1965
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2483137767
- Cited by
- 59
- References
- 1
- FWCI
- 3.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA. https://app.cochat.ai/papers/10.1093/annonc/mdw278
- The paper
- Gremel, G., Lee, R. J., Girotti, M. R., Mandal, A. K., Valpione, S., Garner, G., Ayub, M., Wood, S., Rothwell, D. G., Fusi, A., Wallace, A., Brady, G., Dive, C., Dhomen, N., Lorigan, P., & Marais, R. (2016). Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA. Annals of Oncology. https://doi.org/10.1093/annonc/mdw278
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.